{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:45:15Z","timestamp":1792773915234,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.032","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:26:56Z","timestamp":1792772816000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Exposure of Intravenous Alemtuzumab is Associated with Increased Risk of Adenovirus reactivation in Patients with Non-Malignant Disease Undergoing Allogeneic HCT"],"prefix":"10.1016","author":[{"given":"G","family":"Salinas Cisneros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Avagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LE","family":"Winestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PT","family":"Pauerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JI","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CS","family":"Higham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KA","family":"Shimano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JN","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JR","family":"Long-Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CC","family":"Dvorak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2026.10.032_bib0001","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2020.06.004","article-title":"Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants","volume":"26","author":"Contreras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.02.002","article-title":"Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning","volume":"31","author":"Dvorak","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.10.032_bib0003","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s40262-019-00782-0","article-title":"Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome","volume":"58","author":"Admiraal","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.032_bib0004","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/bloodadvances.2024014836","article-title":"Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation","volume":"9","author":"Admiraal","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.032_bib0005","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0006","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41409-024-02206-5","article-title":"Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience","volume":"59","author":"Barriga","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2026.10.032_bib0007","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/bloodadvances.2024013275","article-title":"Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity","volume":"8","author":"Bognar","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.032_bib0008","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bcp.14955","article-title":"Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation","volume":"88","author":"Dong","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.032_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.03.020","article-title":"High Melphalan Exposure Increases the Risk of Graft-Versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation","volume":"31","author":"Dvorak","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.032_bib0010","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bbmt.2019.03.008","article-title":"Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency","volume":"25","author":"Dvorak","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2026.10.032_bib0011","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1182\/bloodadvances.2024012670","article-title":"Effect of rabbit ATG PK on outcomes after TCR-alphabeta\/CD19-depleted pediatric haploidentical HCT for hematologic malignancy","volume":"8","author":"Dvorak","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.032_bib0012","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","article-title":"Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use","volume":"37","author":"Long-Boyle","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"22","key":"10.1016\/j.jtct.2026.10.032_bib0013","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/bloodadvances.2021005231","article-title":"Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure","volume":"5","author":"Sabulski","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0014","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.032_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.01.268","article-title":"Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","author":"Dvorak","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.032_bib0016","article-title":"Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia","volume":"9","author":"Keogh","year":"2021","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.032_bib0017","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2026.10.032_bib0018","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.032_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/146532401753174098","article-title":"The CD52 antigen and development of the CAMPATH antibodies","volume":"3","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.032_bib0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2026.10.032_bib0022","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/bloodadvances.2022009051","article-title":"Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study","volume":"7","author":"Achini-Gutzwiller","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.12.007","article-title":"Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","volume":"32","author":"Dvorak","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.jtct.2026.10.032_bib0024","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1182\/bloodadvances.2025016915","article-title":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group","volume":"9","author":"Hammoudi","year":"2025","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.jtct.2026.10.032_bib0025","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V128.22.2203.2203","article-title":"Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases","volume":"128","author":"Fukuda","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0026","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbmt.2017.01.071","article-title":"Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab","volume":"23","author":"Marsh","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0027","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","article-title":"Population pharmacokinetic modeling of Thymoglobulin((R)) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing","volume":"54","author":"Admiraal","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.032_bib0028","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaci.2016.12.992","article-title":"Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation","volume":"140","author":"Admiraal","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.032_bib0029","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.2020007905","article-title":"CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation","volume":"137","author":"de Koning","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.032_bib0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcyt.2020.05.005","article-title":"Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation","volume":"22","author":"van Roessel","year":"2020","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.032_bib0031","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jcyt.2024.01.004","article-title":"Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients","volume":"26","author":"Lakkaraja","year":"2024","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.032_bib0032","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jcyt.2023.05.012","article-title":"Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis","volume":"25","author":"Troullioud Lucas","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.032_bib0033","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10238-023-01270-3","article-title":"Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Huang","year":"2024","journal-title":"Clin Exp Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.032_bib0034","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/bloodadvances.2021005584","article-title":"Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation","volume":"6","author":"Lakkaraja","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.10.032_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2019.06.001","article-title":"Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft","volume":"57","author":"Loeff","year":"2019","journal-title":"Transpl Immunol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726008481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:27:01Z","timestamp":1792772821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726008481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S2666636726008481"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.032","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Exposure of Intravenous Alemtuzumab is Associated with Increased Risk of Adenovirus reactivation in Patients with Non-Malignant Disease Undergoing Allogeneic HCT","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}